This antibody treatment, codenamed AZD7442, has not previously shown its effectiveness in people already infected with the virus.
But by managing it before it comes in contact with the virus, Astrogeneka explains in a statement that there are results.
In this case, it reduces the risk of developing symptomatic form by 77%, according to Phase 3 data, i.e. large-scale clinical trials designed to measure its safety and efficacy.
Astrogeneka notes that there are no serious cases of Covit-19 or death.
The trials, conducted in Spain, France, Belgium, the United Kingdom and the United States, involved 5,197 participants, 75% of whom were diagnosed with the disease. The treatment was given inwardly.
“With these excellent results, the AZD7442 could be an important tool in our arsenal, helping people who need more than the vaccine to get back to normal life,” said Myron Levine, a professor at the University of Colorado in the United States. Of the experiment.
“We need different approaches for people who are not well protected by the Govt-19 vaccine,” said Mene Bangalos, a senior official at AstraZeneca, who promised to release additional data after the tests.
The lab states that it will submit a file to health officials for verification under the terms of emergency use or treatment, the development of which is funded by the U.S. government.
AstraZeneca was one of the first to confirm the vaccine against Govt-19, however, this raised questions about its very rare side effects, which limited countries to its use.
In addition, an Oxford University study released on Thursday found that the Pfizer / Bioentech vaccine may be more effective in fighting infections associated with the delta type of corona virus, but its effectiveness is declining faster than the vaccine. ‘
“Music geek. Coffee lover. Devoted food scholar. Web buff. Passionate internet guru.”